Skip to main content
    P

    Prime Medicine, Inc. Common Stock (PRME)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.84
    -0.35 (-8.35%)

    Market Cap: $932.06M

    Last updated: Nov 17, 2026 at 4:31 PM ET

    Prime Medicine, Inc. Common Stock (PRME) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Prime Medicine, Inc. Common Stock (PRME) has a market cap of $932.06M and an enterprise value of $877.17M. It kept -2497.56% of revenue as net income over the last 12 months. Its share count is up 10.81% from a year earlier.

    Total Valuation

    Enterprise value is 5.89% below the market cap, as cash exceeds debt.

    Market Cap$932.06M
    Enterprise Value$877.17M
    Latest price (Nov 17, 2026)$3.84

    Key Dates

    The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 1, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.36% in the quarter ended Sep 30, 2026 and grew 21.86% a year over 2 years.

    Shares Outstanding177.86M
    Shares Change (YoY)+10.81%
    Shares Change (QoQ)+0.36%
    Share Count Growth (2Y CAGR)+21.86%

    Valuation Ratios

    Sales and book value multiples are 96.7x and 80.9x. Its year-end P/S ranged from 33.6x to 346.7x from 2022 to 2025.

    P/S Ratio96.7x
    Forward P/S121.2x
    P/B Ratio80.9x

    Valuation history and multiples

    Price Statistics

    The stock is up 13.95% over 52 weeks and trades 3.50% above its 50-day average.

    Beta (1Y)2.46
    52-Week Change+13.95%
    1-Month Change+0.26%
    3-Month Change+8.47%
    6-Month Change+42.22%
    Total Return (1Y)+13.95%
    Total Return (3Y CAGR)-16.51%
    Return vs SPY (1Y)-3.39%
    Max Drawdown (1Y)-42.25%
    Max Drawdown (3Y)-87.96%
    Sharpe Ratio (1Y)0.09
    Correlation with SPY (1Y)0.38
    50-Day Average$3.71
    200-Day Average$3.51
    52-Week Range$2.67 to $5.91
    RSI (14 Days)46.8
    Average Volume (20 Days)6.04M

    Price chart

    Financial Position

    Current assets cover 1.79x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio1.79x
    Quick Ratio1.79x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -2090.23% and return on assets is -82.46% over the last 12 months.

    Return on Equity (ROE)-2090.23%
    Return on Assets (ROA)-82.46%
    ROA (5Y Average)-63.07%
    Asset Turnover0.02x

    Scores

    PRME has an Altman Z-Score of -7.26, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-7.26
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $7.06M over the last 12 months is up 18.14% from the 12 months before.

    Revenue$7.06M
    Revenue Growth (YoY)+18.14%
    Gross Profit$7.06M
    Operating Income-$182.47M
    Pretax Income-$176.35M
    Net Income-$176.35M
    EBITDA-$174.25M
    Reported EPS (TTM)-$0.98

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 3.95% of the $213.85M in total assets.

    Cash and Equivalents$54.89M
    Total Debt$0
    Net Cash$54.89M
    Net Cash Per Share$0.31
    Working Capital$28.06M
    Shareholder Equity$8.44M
    Book Value Per Share$0.05
    Total Assets$213.85M
    Total Liabilities$205.42M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $848.00K of capital spending, operating cash flow left -$158.54M of free cash flow.

    Operating Cash Flow-$157.69M
    Capital Expenditures$848.00K
    Free Cash Flow-$158.54M
    FCF Per Share-$0.87
    Depreciation and Amortization$9.00M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -2584.24%.

    Gross Margin100.00%
    Operating Margin-2584.24%
    Pretax Margin-2497.56%
    Net Margin-2497.56%
    EBITDA Margin-2467.74%
    FCF Margin-2245.33%

    Growth

    Revenue Growth (5Y CAGR)-2.32%
    Book Value Per Share Growth (2Y CAGR)-22.89%
    Tangible Book Per Share Growth (2Y CAGR)-22.89%

    Revenue and profit by year

    Dividends and Yields

    PRME does not pay a dividend. Its free cash flow yield is -23.21%.

    FCF Yield-23.21%
    Buyback Yield-0.43%
    Shareholder Yield-0.43%

    Peer Position

    Against 7 similar companies, PRME has the highest P/S.

    P/S Ratio96.7x vs 5.4x median
    Revenue Growth (Trailing 4 Quarters, YoY)+18.14% vs -8.07% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 52.55% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+52.55%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About PRME

    What is PRME's market cap?

    Prime Medicine, Inc. Common Stock has a market cap of $932.06M. Its enterprise value, which adds debt and subtracts cash, is $877.17M.

    How many shares of PRME are outstanding?

    Prime Medicine, Inc. Common Stock has 177.86M shares outstanding. The count is up 10.81% from a year earlier.

    Does PRME pay a dividend?

    No. Prime Medicine, Inc. Common Stock does not pay a dividend.

    How much debt does PRME have?

    Prime Medicine, Inc. Common Stock has $0 of total debt and $54.89M of cash and equivalents, a net cash position of $54.89M.